Anifrolumab

The recent approval of anifrolumab highlights what may be a new wave of therapeutic advances made in lupus, according to a presenter at the 2021 Congress of Clinical Rheumatology-East.

This week, Pfizer says a third dose of the vaccine boosts protection, even against the delta variant; US News and World Report ranks Mayo Clinic number 1 for pulmonology and lung surgery; the FDA approves IV selexipag for adults with PAH; and more.

The FDA has approved AstraZeneca’s anifrolumab-fnia, a first-in-class type I interferon receptor antagonist, for treatment of adults with moderate to severe systemic lupus erythematosus, according to a press release.